KALBITOR

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Hereditary AngioedemaAngioedema

43 competitors in Hereditary Angioedema

#DrugCompanyPhaseTrials

1

Neoral

Novartis

Approved

—2

Crestor

AstraZeneca

Approved

—3

Firazyr

Takeda

Phase 3

54

Lanoxin

AAdvanz Pharma

Approved

—5

Andembry

CSL Behring

Approved

16

Cyklokapron

AAmring

Phase 3

17

C1 Esterase Inhibitor

Takeda

Phase 3

88

Dawnzera (autoinjector)

Ionis Pharmaceuticals

Phase 3

69

KALBITOR

Takeda

Phase 3

510

Ruconest

PPharming Technologies B.V.

Approved

1Show 20 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hereditary Angioedema5 trials

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

Completed·Takeda·Phase 3·NCT00456508·147 enrolled

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Completed·Takeda··NCT01059526·81 enrolled

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

Completed·Takeda·Phase 3·NCT00262080·91 enrolled

Show 2 more trials

Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema

Withdrawn·Takeda·Phase 2/3·NCT01253382

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

Completed·Takeda·Phase 3·NCT00457015·96 enrolled

Angioedema1 trial

Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Terminated·Takeda·Phase 2·NCT01343823·79 enrolled

Surgical Blood Loss1 trial

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

Completed·Merck & Co.·Phase 2·NCT00816023·276 enrolled

Cardiopulmonary Bypass1 trial

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

Completed·Merck & Co.·Phase 2·NCT00888940·243 enrolled

Blood Loss1 trial

Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

Terminated·Merck & Co.·Phase 2·NCT00448864·75 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News